Risk of Postoperative Bleeding and Thromboembolic Events in Anticoagulated Patients Undergoing Transurethral Resection of Bladder Tumors

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2025 Feb 5

PMID 39906152

Authors

Thomas Paul Scherer

Cici Dam

Uwe Bieri

Daniel Eberli

Raeto Strebel

Affiliations

Soon will be listed here.

Abstract

Background: Transurethral resection of the bladder (TURB) harbors a high-risk for postoperative bleeding, especially in patients requiring anticoagulation. Recently, direct oral anticoagulants (DOACs) have become a popular alternative to vitamin K antagonists (VKAs), though their impact on TURB complications remains unclear.

Objectives: To assess the postoperative complications of TURB from patients taking DOACs and VKAs.

Design: Retrospective cohort study.

Materials And Methods: We retrospectively identified anticoagulated patients undergoing a TURB at our institution between 2012 and 2022 and divided them into two groups: whether they received VKA or DOAC. Follow-up of each patient was performed for 3 months. Occurrence and time to event of postoperative bleeding and thromboembolic events were recorded. A multivariable regression analysis was performed to assess risk differences.

Results: A total of 167 patients (11.7%) fulfilled the inclusion criteria, of which 102 patients (61.1%) received a DOAC and 65 patients (38.9%) a VKA. Postoperative bleeding led to re-catheterization in 13 (12.8%) DOAC and 6 (9.2%) VKA patients ( = 0.49) and re-intervention in 7 (6.9%) DOAC and 4 (6.2%) VKA patients ( = 0.86). Blood transfusions were administered to 3 DOAC patients (2.9%), none in the VKA group. No thromboembolic events were reported.

Conclusion: TURB carries low morbidity in anticoagulated patients. Thromboembolic events and the need for blood transfusion are infrequent. No substantial difference between the postoperative bleeding risk of patients receiving DOAC or VKA was found. All bleeding complications occurred within 2 weeks, marking it a potentially safe point in time to restart the OAC thereafter.

References

Kuo H, Liu F, Chen J, Cherng Y, Tam K, Tai Y . Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta-analysis. Clin Cardiol. 2020; 43(5):441-449. PMC: 7244304. DOI: 10.1002/clc.23336. View

Konishi T, Washino S, Nakamura Y, Ohshima M, Saito K, Arai Y . Risks and complications of transurethral resection of bladder tumors in patients receiving antiplatelet and/or anticoagulant therapy: a retrospective cohort study. BMC Urol. 2017; 17(1):118. PMC: 5727922. DOI: 10.1186/s12894-017-0309-0. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Aimo A, Giugliano R, De Caterina R . Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?. Circulation. 2018; 138(13):1356-1365. DOI: 10.1161/CIRCULATIONAHA.118.035612. View

Culkin D, Exaire E, Green D, Soloway M, Gross A, Desai M . Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014; 192(4):1026-34. DOI: 10.1016/j.juro.2014.04.103. View

Tikkinen K, Agarwal A, Craigie S, Cartwright R, Gould M, Haukka J . Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev. 2014; 3:150. PMC: 4307154. DOI: 10.1186/2046-4053-3-150. View

van Hoogstraten L, Vrieling A, van der Heijden A, Kogevinas M, Richters A, Kiemeney L . Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023; 20(5):287-304. DOI: 10.1038/s41571-023-00744-3. View

Chan N, Sobieraj-Teague M, Eikelboom J . Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020; 396(10264):1767-1776. DOI: 10.1016/S0140-6736(20)32439-9. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

10.

Devereaux P, Mrkobrada M, Sessler D, Leslie K, Alonso-Coello P, Kurz A . Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370(16):1494-503. DOI: 10.1056/NEJMoa1401105. View

11.

Lock J, Ungeheuer L, Borst P, Swol J, Lob S, Brede E . Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery. Perioper Med (Lond). 2020; 9(1):39. PMC: 7682086. DOI: 10.1186/s13741-020-00170-4. View

12.

Panch S, Montemayor-Garcia C, Klein H . Hemolytic Transfusion Reactions. N Engl J Med. 2019; 381(2):150-162. DOI: 10.1056/NEJMra1802338. View

13.

De Nunzio C, Franco G, Cindolo L, Autorino R, Cicione A, Perdona S . Transuretral resection of the bladder (TURB): analysis of complications using a modified Clavien system in an Italian real life cohort. Eur J Surg Oncol. 2013; 40(1):90-5. DOI: 10.1016/j.ejso.2013.11.003. View

14.

Ording A, Sogaard M, Skjoth F, Grove E, Lip G, Larsen T . Hematuria in anticoagulated patients with atrial fibrillation and urologic cancer. Res Pract Thromb Haemost. 2022; 6(1):e12629. PMC: 8756162. DOI: 10.1002/rth2.12629. View

15.

Schraml J, Do Carmo Silva J, Babjuk M . Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection. Curr Opin Urol. 2018; 28(6):591-597. DOI: 10.1097/MOU.0000000000000542. View

16.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

17.

Eikelboom J, Connolly S, Brueckmann M, Granger C, Kappetein A, Mack M . Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206-14. DOI: 10.1056/NEJMoa1300615. View

18.

Picozzi S, Marenghi C, Ricci C, Bozzini G, Casellato S, Carmignani L . Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. Surg Endosc. 2013; 28(1):116-21. DOI: 10.1007/s00464-013-3136-8. View

19.

Megwalu I, Vlahiotis A, Radwan M, Piccirillo J, Kibel A . Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2007; 53(3):581-9. PMC: 2262100. DOI: 10.1016/j.eururo.2007.10.069. View

20.

Avallone M, Sack B, El-Arabi A, Charles D, Herre W, Radtke A . Ten-Year Review of Perioperative Complications After Transurethral Resection of Bladder Tumors: Analysis of Monopolar and Plasmakinetic Bipolar Cases. J Endourol. 2017; 31(8):767-773. PMC: 5568593. DOI: 10.1089/end.2017.0056. View